The clinical trial data showing superior anti-melanoma effects of ICIs such as pembrolizumab (anti-PD-1), nivolumab (anti-PD-L1), and ipilimumab (anti-CTLA-4), over traditional therapies, has led to their rapid FDA approval (9, 10). Here, PDCD1 is linked to melanoma.